Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2018

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Plimsoller
    wrote on sidst redigeret af
    #1439

    Copy/paste fra Børsen.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Plimsoller
      wrote on sidst redigeret af
      #1440

      Link Preview Image
      Siden findes ikke

      favicon

      (borsen.dk)

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #1441

        Så giver vi Børsen æren Plimsoller:-)

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Plimsoller
          wrote on sidst redigeret af
          #1442

          Jeg mente nu den anden vej rundt, men fik udtrykt mig lidt uklart 🙂

          1 Reply Last reply
          0
          • royalR Offline
            royalR Offline
            royal
            wrote on sidst redigeret af
            #1443

            Arzerra: http://ir.genmab.com/releasedetail.cfm?ReleaseID=1054821

            1 Reply Last reply
            0
            • DarvinD Offline
              DarvinD Offline
              Darvin
              wrote on sidst redigeret af
              #1444

              Novartis intends to transition the commercial availability of Arzerra to limited availability via compassionate use programs for treatment of CLL in non-US markets. Novartis will continue to market for CLL in the US
              Novartis will work with regulatory authorities to establish compassionate use programs so that patients benefitting from Arzerra can remain on treatment
              Genmab receives USD 50 million from Novartis as payment for lost potential milestones and royalties

              1 Reply Last reply
              0
              • J Offline
                J Offline
                jkj
                wrote on sidst redigeret af
                #1445

                Godmorgen, Hvad skal vi mene om det ?

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  JKY_VH
                  wrote on sidst redigeret af
                  #1446

                  Tjah bom, bom, det gælder udelukkende uden for USA og vi får en kompensation på 50 mio. Hvad det betyder på den lange bane, tør jeg ikke spå om.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #1447

                    Min tanke har været, at man ville trække Arzerra fra CLL, hvis der kom hul igennem i MS - nu kommer det så lidt før med kompensation, så tror ikke det betyder alverden. Arzerra er et niche produkt i CLL og med tiden bliver det mindre og mindre

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #1448

                      Ser heller ikke ud til at det betyder alverden https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=466334013&sourcecode=ddk

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #1449

                        https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=466334013&sourcecode=ddk

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #1450

                          Det havde sikkert givet lidt nere over tid, men vi godtager jo også et bud på Genmab i kurs xxxx selv om det sikkert ville blive til på den lange bane

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JKY_VH
                            wrote on sidst redigeret af
                            #1451

                            undskyld gentagelsen.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1452

                              I am wondering why they continue to market for CLL in the US though? Do we know what the split in sales was for Ofa in US vs ROW? Total sales went down 23% from 2016 to 2017, so this is not a total surprise...

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #1453

                                Assumeing royalty income on net sales of Arzerra for 2017 will be roughly DKK50million (?), of which I assume most comes from US, this USD 50 million payment may actually be not such a bad deal really

                                1 Reply Last reply
                                0
                                • royalR Offline
                                  royalR Offline
                                  royal
                                  wrote on sidst redigeret af
                                  #1454

                                  Har vis sagt det før: På discovery kører de en serie der hedder breakthrough. Kl 0100 i nat handlede det om car-t. Medvirkende bla. David Porter, Carl June og Bruce Levine. Kan stadig ses hos yousee. Meget informativ.

                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #1455

                                    Løntoft https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=466342013&sourcecode=ddk

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #1456

                                      Sanofi -2.5% on another bio deal - Sanofi SA agreed to buy Bioverativ Inc. for about $11.6 billion in a bid by France’s biggest drugmaker to add treatments for rare blood disorders to its portfolio.

                                      1 Reply Last reply
                                      0
                                      • O Offline
                                        O Offline
                                        OHW
                                        wrote on sidst redigeret af
                                        #1457

                                        ..hvilket også for SOBI til at stige 14%!

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #1458

                                          Som sukkeralf også antyder er Novartis dealen en frontløber for ny prissætning af ofatumumab inden MS data og godkendelse.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger